meloxicam meloxicam meloxicam, sold under the brand name mobic among others, is a nonsteroidal anti-inflammatory medication (nsaid) used to treat pain and inflammation in rheumatic diseases and osteoarthritis. it is used by mouth or by injection into a vein. it is recommended that it be used for as short a period as possible and at a low dose. meloxicamclinical datatrade namesmobic, metacam, anjeso, othersahfs/drugs.commonographmedlineplusa601242license data us dailymed: meloxicam pregnancycategory au: c routes ofadministrationby mouth, intravenousatc codem01ac06 (who) m01ac56 (who), qm01ac06 (who), qm01ac56 (who)legal statuslegal status au: s4 (prescription only) uk: pom (prescription only) us: ℞-only eu: rx-only pharmacokinetic databioavailability89%protein binding99.4%metabolismliver (cyp2c9 and 3a4-mediated)elimination half-life20 hoursexcretionurine and feces equallyidentifiers iupac name 4-hydroxy-2-methyl-n-(5-methyl-2-thiazolyl)-2h-1,2-benzothiazine-3-carboxamide-1,1-dioxide cas number71125-38-7 ypubchem cid5281106iuphar/bps7220drugbankdb00814 ychemspider10442740 yuniivg2qf83cglkeggd00969 ychebichebi:6741 ychemblchembl599 ypdb ligandmxm (pdbe, rcsb pdb)comptox dashboard (epa)dtxsid1020803 echa infocard100.113.257 chemical and physical dataformulac14h13n3o4s2molar mass351.40 g·mol−13d model (jsmol)interactive image smiles cc1cnc(s1)nc(=o)c\3=c(/o)c2ccccc2s(=o)(=o)n/3c inchi inchi=1s/c14h13n3o4s2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18h,1-2h3,(h,15,16,19) ykey:zrvujxdffkflmg-uhfffaoysa-n y ny (what is this?) (verify) common side effects include abdominal pain, dizziness, swelling, headache, and a rash. serious side effects may include heart disease, stroke, kidney problems, and stomach ulcers. use is not recommended in the third trimester of pregnancy. it blocks cyclooxygenase-2 (cox-2) more than it blocks cyclooxygenase-1 (cox-1). it is in the oxicam family of chemicals and is closely related to piroxicam. meloxicam was patented in 1977 and approved for medical use in the united states in 2000. it was developed by boehringer ingelheim; however, it is also available as a generic medication. in 2020, it was the 28th most commonly prescribed medication in the united states, with more than 19 million prescriptions. an intravenous version of meloxicam (anjeso) was approved for medical use in the united states in february 2020. adverse effects